Subbotina T I, Tenkova T V, Sidorova L V, Shpilyuk G F, Drinevsky V P, Voitsekhovskaya E M, Konstantinov V K, Sominina A A
Leningrad Research Institute of Vaccines and Sera, U.S.S.R.
Acta Virol. 1988 Nov;32(6):494-502.
Vaccination activity and safety of inactivated influenza centrifugal divaccine have been studied in groups of subjects aged 18 to 22, 15 to 16, and 9 to 14 years. The vaccine tested contained either a standard dose (6-8 micrograms) or double a dose (12-16 micrograms) of the haemagglutinin (HA) of influenza viruses A(H1N1) and A(H3N2). The double antigenic load of the vaccine did not enhance its reactogenicity for adults or adolescents aged 15 to 16 years. It enhanced, however, the production of antihaemagglutinine antibodies to the vaccine strains. The range of the antibodies formed and their persistence were independent on the virus dose. The increased dose (12-16 micrograms) of HA decreased the humoral immune response in school children aged from 11 to 14 years. Neither standard nor double dose of the vaccine caused any changes in the biochemical or haematological parameters of blood and urine. No allergic response was registered by the indirect mast cell degranulation (IMCD) test in rats.
已在18至22岁、15至16岁和9至14岁的受试者群体中研究了灭活流感离心双价疫苗的接种活性和安全性。所测试的疫苗含有标准剂量（6 - 8微克）或双倍剂量（12 - 16微克）的甲型流感病毒（H1N1）和甲型流感病毒（H3N2）的血凝素（HA）。疫苗的双倍抗原负荷并未增强其对15至16岁成年人或青少年的反应原性。然而，它增强了针对疫苗株的抗血凝素抗体的产生。所形成抗体的范围及其持久性与病毒剂量无关。增加剂量（12 - 16微克）的HA降低了11至14岁学龄儿童的体液免疫反应。疫苗的标准剂量和双倍剂量均未引起血液和尿液的生化或血液学参数的任何变化。在大鼠的间接肥大细胞脱颗粒（IMCD）试验中未记录到过敏反应。
